alcohol brands

12 registered brands containing alcohol in Kenya.

Alcohol 2D chemical structure

2D structure

Alcohol

PubChem CID 702

Molecular formula: C2H6O

Ethanol affects the brain’s neurons in several ways. It alters their membranes as well as their ion channels, enzymes, and receptors. Alcohol also binds directly to the receptors for acetylcholine, serotonin, GABA, and the NMDA receptors for glutamate. The sedative effects of ethanol are mediated through binding to GABA receptors and glycine receptors (alpha 1 and alpha 2 subunits). It also inhibits NMDA receptor functioning. In its role as an anti-infective, ethanol acts as an osmolyte or dehydrating agent that disrupts the osmotic balance across cell membranes. ... Ethanol is known to affect a large number of membrane proteins that participate in signaling pathways such as neurotransmitter receptors, enzymes, and ion channels, and there is extensive evidence that ethanol interacts with a variety of neurotransmitters. The major actions of ethanol involve enhancing the inhibitory effects of gamma-aminobutyric acid (GABA) at GABAa receptors and blockade of the N-methyl-D-aspartate (NMDA) subtype of glutamate, an excitatory amine acid (EAA) receptor. Animal studies indicate that the acute effects of ethanol result from competitive inhibition of glycine binding to NMDA receptor and disruption of glutamatergic neurotransmission by inhibiting the response of the NMDA receptor. Persistent glycine antagonism and attenuation of glutamatergic neurotransmission by chronic ethanol exposure results in tolerance to ethanol by enhancing EAA neurotransmission and NMDA receptor upregulation. The latter appears to involve selective increases in NMDA R2B subunit concentrations and other molecular changes in specific brain loci. The abrupt withdrawal of ethanol thus produces a hyperexcitable state that leads to the ethanol withdrawal syndrome and excitotoxic neuronal death. GABA-mediated inhibition, which normally acts to limit excitation, is eliminated during ethanol withdrawal syndrome and further intensifies this excitation. In addition, NMDA receptors function to inhibit the release of dopamine in the nucleus accumbens and mesolimbic structures, which modulate the reinforcing action of addictive xenobiotics such as ethanol. By inhibiting NMDA receptor activity, ethanol could increase dopamine release from the nucleus accumbens and ventral tegmental area and could thus create dependence. Chronic ethanol administration also results in tolerance, dependence, and an ethanol withdrawal syndrome, mediated, in part, by desensitization and or downregulation of GABAa receptors. The development of alcoholic ketoacidosis (AKA) requires that a combination of physical and physiologic events occur. The normal response to starvation and depletion of hepatic glycogen stores is for amino acids to be converted to pyruvate. Pyruvate can serve as a substrate for gluconeogenesis, be converted to acetyl-CoA, which can enter the Krebs cycle or can be utilized in various biosynthetic pathways (eg, fatty acid, ketone bodies, cholesterol, and acetylcholine) ... Ethanol metabolism generates NADH, resulting in an excess of reducing potential. This high redox state favors the conversion of pyruvate to lactate, diverting pyruvate from being a substrate for gluconeogenesis. To compensate for the lack of normal metabolic substrates, the body mobilizes fat from adipose tissue and increased fatty acid metabolism as an alternative source of energy. This response is mediated by a decrease in insulin and an increased secretion of glucagon, catecholamines, growth hormone, and cortisol. Fatty acid metabolism results in the formation of acetyl-CoA and it combines with the excess acetate that is generated from ethanol metabolism to form acetoacetate. Most of the acetoacetate is reduced to beta-hydroxybutyrate due to the excess reducing potential or high redox state of the cell. Volume depletion interferes with the renal elimination of acetoacetate and beta-hydroxybutyrate, and contributes to the acidosis. An elevated lactate concentration may result from shunting from pyruvate or

Source: PubChem (NCBI) · compound 702

Product Manufacturer Status Country
CEPACOL THROAT LOZENGES
CETYLPYRIDINIUM CHLORIDE 1.47MG & BENZYL ALCOHOL 6.50MG
Imperial Managed Solutions Registered Kenya
DOLAREN GEL
DICLOFENAC DIETHYLAMINE 10MG, METHYLSALICYLATE 100MG, BENZYL ALCOHOL 10MG, MENTHOL 50MG
Danvantri Enterprises Registered Kenya
FIGOPAR
5000 IU/ML (5ML INJECTION)
Pharmamed Solution Registered Kenya
FRESHBURST LISTERINE
THYMOL 12,78 MG; ALCOHOL 95% 4,54 MG; ZINC CHLORIDE 18,00 MG PER 20 ML
Surgipharm Registered Kenya
GERMIDINE GARGLE
POVIDONE IODINE USP 2%W/V , ABSOLUTE ALCOHOL CONTENT 8.38%V/V
Europa Healthcare Registered Kenya
KALUMA GEL
WINTERGREEN OIL 15%, MENTHOL 5%, TURPENTINE OIL 3%, EUCALYPTUS OIL 2%, LINSEED OIL 3%, BENZYL ALCOHOL 1%
Shalina Healthcare Registered Kenya
LISTERINE ANTISEPTIC
DENATURED ALCOHOL MENTHOL 0.02%, THYMOL, EUCALYPTOL, METHYL SALICYLATE, L-MENTHOL, BENZOIC ACID, SODIUM BENZOATE, POLOXAMER 407, CARAMEL-ACID PROOF, WATER PURIFIED
Surgipharm Registered Kenya
LISTERINE COOL MINT
THYMOL 12,780 MG; ALCOHOL (95%) V/V 4,530 ML PER 20 ML
Surgipharm Registered Kenya
MINFEN GEL
DICLOFENAC SODIUM 1%W/W, LINSEED OIL 3% W/W, METHYL SALICYLATE 10%W/W, MENTHOL 2% W/W AND BENZYL ALCOHOL 1% W/W
Zengenta Pharmaceuticals Registered Kenya
SANISCRUB E
CHLORHEXIDINE GLUCONATE SOLUTION BP 2.5% V/V EQ. TO CHLORHEXIDINE GLUCONATE 0.5% W/V ETHANOL
Harleys Registered Kenya
SONATEC MOUTHWASH
CETYLPYRIDINIUM CHLORIDE 0.05 W/W ALCOHOL (95%) 14.7%V/V
Regal Pharmaceuticals Registered Kenya
VITAMIN E
VITAMIN E ALCOHOL USP AS D-ALPHA TOCOPHEROL 200 I.U
Aglowmed Registered Kenya